Scandion Oncology (Sweden) Probability of Future Stock Price Finishing Under 0.13
| SCOL Stock | SEK 0.02 0 5.41% |
Scandion |
Scandion Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Scandion Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Scandion Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Scandion Oncology generated a negative expected return over the last 90 days | |
| Scandion Oncology has high historical volatility and very poor performance | |
| Scandion Oncology has some characteristics of a very speculative penny stock | |
| Scandion Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M). | |
| Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Scandion Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Scandion Stock often depends not only on the future outlook of the current and potential Scandion Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Scandion Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.6 M | |
| Cash And Short Term Investments | 105.7 M |
Scandion Oncology Technical Analysis
Scandion Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Scandion Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Scandion Oncology AS. In general, you should focus on analyzing Scandion Stock price patterns and their correlations with different microeconomic environments and drivers.
Scandion Oncology Predictive Forecast Models
Scandion Oncology's time-series forecasting models is one of many Scandion Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Scandion Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Scandion Oncology
Checking the ongoing alerts about Scandion Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Scandion Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Scandion Oncology generated a negative expected return over the last 90 days | |
| Scandion Oncology has high historical volatility and very poor performance | |
| Scandion Oncology has some characteristics of a very speculative penny stock | |
| Scandion Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (51.7 M) with loss before overhead, payroll, taxes, and interest of (32.32 M). | |
| Scandion Oncology AS has accumulated about 131.54 M in cash with (49.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.